Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Other Non-Current Liabilities (2022 - 2025)

Envoy Medical's Other Non-Current Liabilities history spans 4 years, with the latest figure at $24000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $24000.0 for Q4 2025, down 97.31% from a year ago — trailing twelve months through Dec 2025 was $24000.0 (down 97.31% YoY), and the annual figure for FY2025 was $24000.0, down 97.31%.
  • Other Non-Current Liabilities for Q4 2025 was $24000.0 at Envoy Medical, down from $891000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $34.0 million in Q4 2022 to a low of $14000.0 in Q2 2025.
  • The 4-year median for Other Non-Current Liabilities is $1.1 million (2023), against an average of $4.0 million.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 1228.31% in 2024, then tumbled 99.27% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $34.0 million in 2022, then plummeted by 94.34% to $1.9 million in 2023, then crashed by 53.67% to $891000.0 in 2024, then crashed by 97.31% to $24000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $24000.0, $891000.0, and $14000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.